FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134876019> ?p ?o ?g. }

• W3134876019 abstract "ModraDoc006 is an oral formulation of docetaxel, which is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in patients with different types of advanced solid tumors, but up to this point in time not in patients with metastatic castration-resistant prostate cancer (mCRPC).We assessed safety and pharmacokinetics (PK) of ModraDoc006/r to establish the recommended phase 2 dose (RP2D) in patients with mCRPC.mCRPC patients, treatment naïve or following abiraterone or enzalutamide treatment, were included. Dose-escalation of ModraDoc006/r was based on safety and docetaxel PK. Antitumor activity was assessed by serum prostate-specific antigen (PSA) and radiological evaluation.Cohort 1 (n = 5) received once weekly ModraDoc006 30 mg with ritonavir 100 mg in the morning, and ModraDoc006 20 mg with ritonavir 100 mg in the evening (30-20/100-100). The mean docetaxel area under the plasma concentration-time curve (mAUC0-inf) was 461 ng/mL × h with 1 dose limiting toxicity (DLT); grade 3 alanine transferase increase. In cohort 2 (n = 6, ModraDoc006/r 30-20/200-200), the mAUC0-inf was 1687 ng/mL × h with 2 DLTs; grade 3 diarrhea and mucositis. In cohort 3A (n = 6, ModraDoc006/r 30-20/200-100), the mAUC0-inf was 1517 ng/mL × h with 1 DLT; grade 3 diarrhea. In cohort 3B (n = 3, ModraDoc006/r 20-20/200-100), the mAUC0-inf was 558 ng/mL × h without DLTs. The mAUC0-inf exceeded estimated exposures of intravenous docetaxel in cohort 2 and 3A, was lower in cohort 1 and was in range in cohort 3B. PSA decreases of >50% occurred in 6/10 evaluable patients throughout the various cohorts. In five radiological evaluable patients, two confirmed partial responses were observed.The RP2D was established at weekly ModraDoc006/r 30-20/200-100. Observed PSA and radiological responses suggest promising clinical activity. These results have led to an ongoing randomized Phase 2b study, comparing weekly ModraDoc006/r with 3-weekly IV docetaxel in patients with mCRPC." @default.
• W3134876019 created "2021-03-15" @default.
• W3134876019 creator A5008239479 @default.
• W3134876019 creator A5030111917 @default.
• W3134876019 creator A5031117246 @default.
• W3134876019 creator A5031888869 @default.
• W3134876019 creator A5036825889 @default.
• W3134876019 creator A5048423409 @default.
• W3134876019 creator A5056917101 @default.
• W3134876019 creator A5062227574 @default.
• W3134876019 creator A5062791488 @default.
• W3134876019 creator A5068302495 @default.
• W3134876019 creator A5081043422 @default.
• W3134876019 creator A5084733864 @default.
• W3134876019 date "2021-03-12" @default.
• W3134876019 modified "2023-10-01" @default.
• W3134876019 title "<scp>ModraDoc006</scp> , an oral docetaxel formulation in combination with ritonavir ( <scp>ModraDoc006</scp> /r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study" @default.
• W3134876019 cites W1541952204 @default.
• W3134876019 cites W1905936368 @default.
• W3134876019 cites W1999742630 @default.
• W3134876019 cites W2016353182 @default.
• W3134876019 cites W2032268660 @default.
• W3134876019 cites W2069769979 @default.
• W3134876019 cites W2076709420 @default.
• W3134876019 cites W2095353714 @default.
• W3134876019 cites W2120292596 @default.
• W3134876019 cites W2126871433 @default.
• W3134876019 cites W2135465113 @default.
• W3134876019 cites W2145962128 @default.
• W3134876019 cites W2171698773 @default.
• W3134876019 cites W2278392405 @default.
• W3134876019 cites W2498821312 @default.
• W3134876019 cites W2598906980 @default.
• W3134876019 cites W2762035816 @default.
• W3134876019 cites W2906445288 @default.
• W3134876019 cites W2916178763 @default.
• W3134876019 doi "https://doi.org/10.1002/cnr2.1367" @default.
• W3134876019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8388171" @default.
• W3134876019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33709626" @default.
• W3134876019 hasPublicationYear "2021" @default.
• W3134876019 type Work @default.
• W3134876019 sameAs 3134876019 @default.
• W3134876019 citedByCount "6" @default.
• W3134876019 countsByYear W31348760192021 @default.
• W3134876019 countsByYear W31348760192022 @default.
• W3134876019 countsByYear W31348760192023 @default.
• W3134876019 crossrefType "journal-article" @default.
• W3134876019 hasAuthorship W3134876019A5008239479 @default.
• W3134876019 hasAuthorship W3134876019A5030111917 @default.
• W3134876019 hasAuthorship W3134876019A5031117246 @default.
• W3134876019 hasAuthorship W3134876019A5031888869 @default.
• W3134876019 hasAuthorship W3134876019A5036825889 @default.
• W3134876019 hasAuthorship W3134876019A5048423409 @default.
• W3134876019 hasAuthorship W3134876019A5056917101 @default.
• W3134876019 hasAuthorship W3134876019A5062227574 @default.
• W3134876019 hasAuthorship W3134876019A5062791488 @default.
• W3134876019 hasAuthorship W3134876019A5068302495 @default.
• W3134876019 hasAuthorship W3134876019A5081043422 @default.
• W3134876019 hasAuthorship W3134876019A5084733864 @default.
• W3134876019 hasBestOaLocation W31348760192 @default.
• W3134876019 hasConcept C112705442 @default.
• W3134876019 hasConcept C121608353 @default.
• W3134876019 hasConcept C126322002 @default.
• W3134876019 hasConcept C126894567 @default.
• W3134876019 hasConcept C142462285 @default.
• W3134876019 hasConcept C143998085 @default.
• W3134876019 hasConcept C203014093 @default.
• W3134876019 hasConcept C2776551883 @default.
• W3134876019 hasConcept C2778496288 @default.
• W3134876019 hasConcept C2779298103 @default.
• W3134876019 hasConcept C2780192828 @default.
• W3134876019 hasConcept C2781190966 @default.
• W3134876019 hasConcept C29730261 @default.
• W3134876019 hasConcept C2993143319 @default.
• W3134876019 hasConcept C3013748606 @default.
• W3134876019 hasConcept C61367390 @default.
• W3134876019 hasConcept C71924100 @default.
• W3134876019 hasConcept C90924648 @default.
• W3134876019 hasConcept C98274493 @default.
• W3134876019 hasConceptScore W3134876019C112705442 @default.
• W3134876019 hasConceptScore W3134876019C121608353 @default.
• W3134876019 hasConceptScore W3134876019C126322002 @default.
• W3134876019 hasConceptScore W3134876019C126894567 @default.
• W3134876019 hasConceptScore W3134876019C142462285 @default.
• W3134876019 hasConceptScore W3134876019C143998085 @default.
• W3134876019 hasConceptScore W3134876019C203014093 @default.
• W3134876019 hasConceptScore W3134876019C2776551883 @default.
• W3134876019 hasConceptScore W3134876019C2778496288 @default.
• W3134876019 hasConceptScore W3134876019C2779298103 @default.
• W3134876019 hasConceptScore W3134876019C2780192828 @default.
• W3134876019 hasConceptScore W3134876019C2781190966 @default.
• W3134876019 hasConceptScore W3134876019C29730261 @default.
• W3134876019 hasConceptScore W3134876019C2993143319 @default.
• W3134876019 hasConceptScore W3134876019C3013748606 @default.
• W3134876019 hasConceptScore W3134876019C61367390 @default.
• W3134876019 hasConceptScore W3134876019C71924100 @default.
• W3134876019 hasConceptScore W3134876019C90924648 @default.
• W3134876019 hasConceptScore W3134876019C98274493 @default.
• W3134876019 hasIssue "4" @default.
• W3134876019 hasLocation W31348760191 @default.

• next